BOSTON SCIENTIFIC CORP (BSX.DE) Stock Fundamental Analysis

Europe • Frankfurt Stock Exchange • FRA:BSX • US1011371077

65.6 EUR
-11.6 (-15.03%)
Last: Feb 4, 2026, 07:00 PM
Fundamental Rating

5

Overall BSX gets a fundamental rating of 5 out of 10. We evaluated BSX against 68 industry peers in the Health Care Equipment & Supplies industry. BSX scores excellent on profitability, but there are some minor concerns on its financial health. BSX is valued quite expensive, but it does show an excellent growth.


Dividend Valuation Growth Profitability Health

7

1. Profitability

1.1 Basic Checks

  • In the past year BSX was profitable.
  • BSX had a positive operating cash flow in the past year.
  • Of the past 5 years BSX 4 years were profitable.
  • Each year in the past 5 years BSX had a positive operating cash flow.
BSX.DE Yearly Net Income VS EBIT VS OCF VS FCFBSX.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1B 2B 3B 4B

1.2 Ratios

  • With a decent Return On Assets value of 6.54%, BSX is doing good in the industry, outperforming 75.00% of the companies in the same industry.
  • The Return On Equity of BSX (11.93%) is better than 72.06% of its industry peers.
  • BSX's Return On Invested Capital of 8.09% is fine compared to the rest of the industry. BSX outperforms 70.59% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for BSX is below the industry average of 9.62%.
  • The last Return On Invested Capital (8.09%) for BSX is above the 3 year average (6.59%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 6.54%
ROE 11.93%
ROIC 8.09%
ROA(3y)3.72%
ROA(5y)2.77%
ROE(3y)6.77%
ROE(5y)5.1%
ROIC(3y)6.59%
ROIC(5y)5.7%
BSX.DE Yearly ROA, ROE, ROICBSX.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 20 30

1.3 Margins

  • BSX has a better Profit Margin (14.42%) than 83.82% of its industry peers.
  • BSX's Profit Margin has declined in the last couple of years.
  • With an excellent Operating Margin value of 19.40%, BSX belongs to the best of the industry, outperforming 82.35% of the companies in the same industry.
  • BSX's Operating Margin has been stable in the last couple of years.
  • BSX has a Gross Margin of 68.57%. This is in the better half of the industry: BSX outperforms 77.94% of its industry peers.
  • BSX's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 19.4%
PM (TTM) 14.42%
GM 68.57%
OM growth 3Y0.91%
OM growth 5Y1.48%
PM growth 3Y10.12%
PM growth 5Y-24.05%
GM growth 3Y-0.15%
GM growth 5Y-0.56%
BSX.DE Yearly Profit, Operating, Gross MarginsBSX.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. Health

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), BSX is destroying value.
  • BSX has more shares outstanding than it did 1 year ago.
  • BSX has more shares outstanding than it did 5 years ago.
  • The debt/assets ratio for BSX is higher compared to a year ago.
BSX.DE Yearly Shares OutstandingBSX.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B
BSX.DE Yearly Total Debt VS Total AssetsBSX.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 10B 20B 30B

2.2 Solvency

  • BSX has an Altman-Z score of 4.55. This indicates that BSX is financially healthy and has little risk of bankruptcy at the moment.
  • With a decent Altman-Z score value of 4.55, BSX is doing good in the industry, outperforming 79.41% of the companies in the same industry.
  • BSX has a debt to FCF ratio of 3.03. This is a good value and a sign of high solvency as BSX would need 3.03 years to pay back of all of its debts.
  • Looking at the Debt to FCF ratio, with a value of 3.03, BSX is in the better half of the industry, outperforming 75.00% of the companies in the same industry.
  • BSX has a Debt/Equity ratio of 0.48. This is a healthy value indicating a solid balance between debt and equity.
  • BSX has a Debt to Equity ratio (0.48) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity 0.48
Debt/FCF 3.03
Altman-Z 4.55
ROIC/WACC0.82
WACC9.85%
BSX.DE Yearly LT Debt VS Equity VS FCFBSX.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5B 10B 15B 20B

2.3 Liquidity

  • BSX has a Current Ratio of 1.51. This is a normal value and indicates that BSX is financially healthy and should not expect problems in meeting its short term obligations.
  • BSX has a Current ratio (1.51) which is comparable to the rest of the industry.
  • A Quick Ratio of 0.96 indicates that BSX may have some problems paying its short term obligations.
  • Looking at the Quick ratio, with a value of 0.96, BSX is in line with its industry, outperforming 41.18% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.51
Quick Ratio 0.96
BSX.DE Yearly Current Assets VS Current LiabilitesBSX.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

8

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 25.00% over the past year.
  • BSX shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 9.56% yearly.
  • Looking at the last year, BSX shows a very strong growth in Revenue. The Revenue has grown by 21.62%.
  • The Revenue has been growing by 9.30% on average over the past years. This is quite good.
EPS 1Y (TTM)25%
EPS 3Y15.48%
EPS 5Y9.56%
EPS Q2Q%19.05%
Revenue 1Y (TTM)21.62%
Revenue growth 3Y12.1%
Revenue growth 5Y9.3%
Sales Q2Q%20.34%

3.2 Future

  • The Earnings Per Share is expected to grow by 15.06% on average over the next years. This is quite good.
  • Based on estimates for the next years, BSX will show a quite strong growth in Revenue. The Revenue will grow by 12.60% on average per year.
EPS Next Y22.12%
EPS Next 2Y18.13%
EPS Next 3Y16.37%
EPS Next 5Y15.06%
Revenue Next Year20.92%
Revenue Next 2Y16.08%
Revenue Next 3Y14.31%
Revenue Next 5Y12.6%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
BSX.DE Yearly Revenue VS EstimatesBSX.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 10B 20B 30B
BSX.DE Yearly EPS VS EstimatesBSX.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 1 2 3 4 5

More info and screens

Find the best growth stocksShow best growing peers

3

4. Valuation

4.1 Price/Earnings Ratio

  • BSX is valuated quite expensively with a Price/Earnings ratio of 26.24.
  • BSX's Price/Earnings ratio is a bit cheaper when compared to the industry. BSX is cheaper than 61.76% of the companies in the same industry.
  • Compared to an average S&P500 Price/Earnings ratio of 28.25, BSX is valued at the same level.
  • With a Price/Forward Earnings ratio of 22.14, BSX is valued on the expensive side.
  • BSX's Price/Forward Earnings is on the same level as the industry average.
  • BSX is valuated at similar levels of the S&P average when we compare the Price/Forward Earnings ratio to 27.50, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 26.24
Fwd PE 22.14
BSX.DE Price Earnings VS Forward Price EarningsBSX.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, BSX is valued a bit more expensive than 63.24% of the companies in the same industry.
  • BSX's Price/Free Cash Flow is on the same level as the industry average.
Industry RankSector Rank
P/FCF 30.07
EV/EBITDA 24.54
BSX.DE Per share dataBSX.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10

4.3 Compensation for Growth

  • The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
  • BSX has a very decent profitability rating, which may justify a higher PE ratio.
  • BSX's earnings are expected to grow with 16.37% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.19
PEG (5Y)2.74
EPS Next 2Y18.13%
EPS Next 3Y16.37%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for BSX!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

BOSTON SCIENTIFIC CORP

FRA:BSX (2/4/2026, 7:00:00 PM)

65.6

-11.6 (-15.03%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)10-22
Earnings (Next)02-04
Inst Owners94.07%
Inst Owner ChangeN/A
Ins Owners0.15%
Ins Owner ChangeN/A
Market Cap97.25B
Revenue(TTM)19.35B
Net Income(TTM)2.79B
Analysts85.5
Price Target108.94 (66.07%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)3.27%
Min EPS beat(2)2.49%
Max EPS beat(2)4.06%
EPS beat(4)4
Avg EPS beat(4)5.68%
Min EPS beat(4)2.49%
Max EPS beat(4)10.56%
EPS beat(8)8
Avg EPS beat(8)6.15%
EPS beat(12)12
Avg EPS beat(12)5.77%
EPS beat(16)15
Avg EPS beat(16)4.37%
Revenue beat(2)2
Avg Revenue beat(2)1.69%
Min Revenue beat(2)0.96%
Max Revenue beat(2)2.43%
Revenue beat(4)4
Avg Revenue beat(4)1.6%
Min Revenue beat(4)0.96%
Max Revenue beat(4)2.43%
Revenue beat(8)8
Avg Revenue beat(8)2.16%
Revenue beat(12)11
Avg Revenue beat(12)2.08%
Revenue beat(16)13
Avg Revenue beat(16)1.61%
PT rev (1m)-0.14%
PT rev (3m)-1.2%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0.01%
EPS NY rev (1m)-0.01%
EPS NY rev (3m)1.76%
Revenue NQ rev (1m)0.04%
Revenue NQ rev (3m)0.13%
Revenue NY rev (1m)0.01%
Revenue NY rev (3m)1%
Valuation
Industry RankSector Rank
PE 26.24
Fwd PE 22.14
P/S 5.94
P/FCF 30.07
P/OCF 24.85
P/B 4.91
P/tB N/A
EV/EBITDA 24.54
EPS(TTM)2.5
EY3.81%
EPS(NY)2.96
Fwd EY4.52%
FCF(TTM)2.18
FCFY3.33%
OCF(TTM)2.64
OCFY4.02%
SpS11.04
BVpS13.35
TBVpS-1.13
PEG (NY)1.19
PEG (5Y)2.74
Graham Number27.4
Profitability
Industry RankSector Rank
ROA 6.54%
ROE 11.93%
ROCE 10.04%
ROIC 8.09%
ROICexc 8.38%
ROICexgc 28.19%
OM 19.4%
PM (TTM) 14.42%
GM 68.57%
FCFM 19.76%
ROA(3y)3.72%
ROA(5y)2.77%
ROE(3y)6.77%
ROE(5y)5.1%
ROIC(3y)6.59%
ROIC(5y)5.7%
ROICexc(3y)6.75%
ROICexc(5y)5.93%
ROICexgc(3y)22.84%
ROICexgc(5y)19.53%
ROCE(3y)8.18%
ROCE(5y)7.08%
ROICexgc growth 3Y9.18%
ROICexgc growth 5Y7.17%
ROICexc growth 3Y4.96%
ROICexc growth 5Y5.6%
OM growth 3Y0.91%
OM growth 5Y1.48%
PM growth 3Y10.12%
PM growth 5Y-24.05%
GM growth 3Y-0.15%
GM growth 5Y-0.56%
F-Score6
Asset Turnover0.45
Health
Industry RankSector Rank
Debt/Equity 0.48
Debt/FCF 3.03
Debt/EBITDA 2.18
Cap/Depr 59.36%
Cap/Sales 4.14%
Interest Coverage 250
Cash Conversion 90.6%
Profit Quality 136.98%
Current Ratio 1.51
Quick Ratio 0.96
Altman-Z 4.55
F-Score6
WACC9.85%
ROIC/WACC0.82
Cap/Depr(3y)57.82%
Cap/Depr(5y)54.13%
Cap/Sales(3y)4.78%
Cap/Sales(5y)4.85%
Profit Quality(3y)134.31%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)25%
EPS 3Y15.48%
EPS 5Y9.56%
EPS Q2Q%19.05%
EPS Next Y22.12%
EPS Next 2Y18.13%
EPS Next 3Y16.37%
EPS Next 5Y15.06%
Revenue 1Y (TTM)21.62%
Revenue growth 3Y12.1%
Revenue growth 5Y9.3%
Sales Q2Q%20.34%
Revenue Next Year20.92%
Revenue Next 2Y16.08%
Revenue Next 3Y14.31%
Revenue Next 5Y12.6%
EBIT growth 1Y30.66%
EBIT growth 3Y13.12%
EBIT growth 5Y10.92%
EBIT Next Year37.52%
EBIT Next 3Y20.65%
EBIT Next 5Y17.42%
FCF growth 1Y125.15%
FCF growth 3Y26.15%
FCF growth 5Y16.61%
OCF growth 1Y96.47%
OCF growth 3Y22.44%
OCF growth 5Y13.34%

BOSTON SCIENTIFIC CORP / BSX.DE FAQ

What is the ChartMill fundamental rating of BOSTON SCIENTIFIC CORP (BSX.DE) stock?

ChartMill assigns a fundamental rating of 6 / 10 to BSX.DE.


What is the valuation status for BSX stock?

ChartMill assigns a valuation rating of 3 / 10 to BOSTON SCIENTIFIC CORP (BSX.DE). This can be considered as Overvalued.


How profitable is BOSTON SCIENTIFIC CORP (BSX.DE) stock?

BOSTON SCIENTIFIC CORP (BSX.DE) has a profitability rating of 7 / 10.


What is the valuation of BOSTON SCIENTIFIC CORP based on its PE and PB ratios?

The Price/Earnings (PE) ratio for BOSTON SCIENTIFIC CORP (BSX.DE) is 26.24 and the Price/Book (PB) ratio is 4.91.


Can you provide the expected EPS growth for BSX stock?

The Earnings per Share (EPS) of BOSTON SCIENTIFIC CORP (BSX.DE) is expected to grow by 22.12% in the next year.